Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2813-2818
Published online before print October 5, 2006, doi: 10.1161/01.ATV.0000249407.92147.12
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/12/2813    most recent
01.ATV.0000249407.92147.12v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schäfer, A.
Right arrow Articles by Bauersachs, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schäfer, A.
Right arrow Articles by Bauersachs, J.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2813.)
© 2006 American Heart Association, Inc.


Thrombosis

Soluble Guanylyl Cyclase Activation With HMR1766 Attenuates Platelet Activation in Diabetic Rats

Andreas Schäfer; Ulrike Flierl; Anna Kobsar; Martin Eigenthaler; Georg Ertl; Johann Bauersachs

From the Medizinische Klinik und Poliklinik I (A.S., U.F., G.E., J.B.), Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg, and the Institut für Klinische Biochemie und Pathobiochemie (A.K., M.E.), Julius-Maximilians-Universität Würzburg, Germany.

Correspondence to Andreas Schäfer, MD, Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany. E-mail a.schaefer{at}medizin.uni-wuerzburg.de

Objective— Platelet activation significantly contributes to cardiovascular morbidity and mortality in diabetes. An association between impaired NO-mediated platelet inhibition and platelet activation has recently been demonstrated in experimental diabetes. Guanylyl cyclase activation enhances the reduced signaling via the NO/cGMP pathway. We investigated whether chronic guanylyl cyclase activation would beneficially modulate platelet activation in experimental diabetes mellitus.

Methods and Results— Diabetes was induced by streptozotocin-injection in male Wistar rats. After 2 weeks, treatment with either placebo or the guanylyl cyclase activator HMR1766 (10 mg/kg twice daily by gavage) was initiated. Two weeks later, in vivo platelet activation and in vitro platelet reactivity were assessed. Chronic treatment with HMR1766 enhanced NO/cGMP-mediated signaling in platelets from diabetic rats determined by in vivo phosphorylation of platelet vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239. In parallel, platelet-binding of fibrinogen, surface-expression of P-selectin, appearance of platelet-derived microparticles, and platelet-aggregates with other blood cells were significantly reduced by chronic treatment with HMR1766.

Conclusion— Chronic activation of soluble guanylyl cyclase in diabetic rats improved markers of platelet activation and is a rationale approach for prevention of adverse cardiovascular events in diabetes.

Diabetes is associated with progressive platelet activation in vivo and thromboembolic complications. Chronic treatment with the direct guanylyl cyclase activator HMR1766 in rats with diabetes improved NO/cGMP signaling and reduced platelet activation in vivo and in vitro.


Key Words: guanylyl cyclase • platelet activation • diabetes




This article has been cited by other articles:


Home page
Eur J Heart FailHome page
A. Schafer, D. Fraccarollo, J. Widder, M. Eigenthaler, G. Ertl, and J. Bauersachs
Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer
Eur J Heart Fail, April 1, 2009; 11(4): 336 - 341.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
P. Gresele, P. Pignatelli, G. Guglielmini, R. Carnevale, A. M. Mezzasoma, A. Ghiselli, S. Momi, and F. Violi
Resveratrol, at Concentrations Attainable with Moderate Wine Consumption, Stimulates Human Platelet Nitric Oxide Production
J. Nutr., September 1, 2008; 138(9): 1602 - 1608.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
B. Kemp-Harper and R. Feil
Meeting Report: cGMP Matters
Sci. Signal., March 4, 2008; 1(9): pe12 - pe12.
[Abstract] [Full Text] [PDF]